Publications

Publications2024-04-11T18:45:29+00:00

KNOW THE SCORE.

ClarityDX Prostate is a blood-based diagnostic test that provides a risk score based on clinical and biological biomarkers to help patients and their physicians make an informed decision after an elevated PSA test result.

EV-Fingerprint test predicts aggressive prostate cancer

June 23rd, 2023|Article, Publication|

Published 17 June 2023

Clinical analysis of EV- Fingerprint to predict grade group 3 and above prostate cancer and avoid prostate biopsy

Adrian FaireyRobert J. PaproskiDesmond PinkDeborah L. SosnowskiCatalina VasquezBryan DonnellyEric HyndmanArmen AprikianAdam KinnairdPerrin H. BeattyJohn D. Lewis

Abstract
There is an unmet clinical need for minimally invasive diagnostic tests to improve the detection of grade group (GG) ≥3 prostate cancer relative to prostate antigen-specific risk calculators. We determined the accuracy of the blood-based extracellular vesicle (EV) biomarker assay (EV Fingerprint test) at the point of a prostate biopsy decision to predict GG ≥3 from GG ≤2 and avoid unnecessary biopsies.
This study analyzed 415 men referred to urology clinics and scheduled for a prostate biopsy, were recruited to the APCaRI 01 prospective cohort study. The EV machine learning analysis platform was used to generate predictive EV models from microflow data. Logistic regression was then used to analyze the combined EV models and patient clinical data and generate the patients’ risk score for GG ≥3 prostate cancer.
The EV-Fingerprint test was evaluated using the area under the curve (AUC) in discrimination of GG ≥3 from GG ≤2 and benign disease on initial biopsy. EV-Fingerprint identified GG ≥3 cancer patients with high accuracy (0.81 AUC) at 95% sensitivity and 97% negative predictive value. Using a 7.85% probability cutoff, 95% of men with GG ≥3 would have been recommended a biopsy while avoiding 144 unnecessary biopsies (35%) and missing four GG ≥3 cancers (5%). Conversely, a 5% cutoff would have avoided 31 unnecessary biopsies (7%), missing no GG ≥3 cancers (0%).
EV-Fingerprint accurately predicted GG ≥3 prostate cancer and would have significantly reduced unnecessary prostate biopsies.

Cytometry Part A: Antibody titrations are critical for microflow cytometric analysis of extracellular vesicles

June 14th, 2023|Publication, Technical Notes|

TECHNICAL NOTE

Optimization of flow cytometry assays for extracellular vesicles (EVs) often fail to include appropriate reagent titrations – the most critically antibody titration is either not performed or is incomplete. Using nonoptimal antibody concentration is one of the main sources of error leading to a lack of reproducible data. Antibody titration for the analysis of antigens on the surface of EVs is challenging for a variety of technical reasons. Using platelets as surrogates for cells and platelet-derived particles as surrogates for EV populations, we demonstrate our process for antibody titration, highlighting some of the key analysis parameters that may confound and surprise new researchers moving into the field of EV research. Additional care must be exercised to ensure instrument and reagent controls are utilized appropriately. Complete graphical analysis of positive and negative signal intensities, concentration, and separation or stain index data is highly beneficial when paired with visual analysis of the cytometry data. Using analytical flow cytometry procedures optimized for cells for EV analysis can lead to misleading and nonreproducible results.

Molecular Oncology: Building predictive disease models using extracellular vesicle microscale flow cytometry and machine learning

January 9th, 2023|Publication|

We developed the extracellular vesicle machine learning analysis platform (EVMAP) to improve the prediction of diseases such as cancer. The platform combines extracellular vesicle analysis using microscale cytometry with a machine learning approach to generate predictive models. In this work, we utilized EVMAP to generate a blood test to predict high-grade prostate cancer in men that was significantly more accurate than the prostate-specific antigen test. This platform could be applied to many different diseases.

BMJ Open Cohort Profile Article: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada

October 16th, 2020|Publication|

The APCaRI Registry and Biorepository, established in 2014, facilitates the collection of clinical and patient-reported data plus biospecimens, to measure prostate cancer outcomes and support the development and clinical translation of innovative technologies. The ultimate goal is to better diagnose and predict outcomes for patients with prostate cancer.

AUTHOR: CATALINA VASQUEZ, MICHAEL KOLINSKY, RUME DJEBAH, MAXWELL UHLICH, BRYAN DONNELLY, ADRIAN S FAIREY, ERIC HYNDMAN, NAWAID USMANI, JACKSON WU, PETER VENNER, DEAN RUETHER, GERALD TODD, MICHAEL CHETNER, R TRAFFORD CRUMP, PERRIN H BEATTY, JOHN D LEWIS

Cowpea mosaic virus nanoparticles for cancer imaging and therapy

November 6th, 2019|Publication|

Nanoparticle platforms are attractive for theranostic applications due to their multifunctionality and multivalency. Some of the most promising nano-scale scaffolds have been co-opted from nature, such as the cowpea mosaic virus (CPMV). What makes CPMV so promising? They are non-infectious and nontoxic to humans and safe for use in intravital imaging and drug delivery. Click on the link to read more.

AUTHOR: PERRIN BEATTY AND JOHN LEWIS

PROSPeCT: A Predictive Research Online System for Prostate Cancer Tasks

May 22nd, 2019|Publication|

We are pleased to present PROSPeCT, a user-friendly online clinical information system that offers an efficient way to query APCaRIs (www.APCaRI.ca) robust and expanding patient database to generate relevant and accurate results. Read the details in our article published in the Journal of Clinical Oncology – Clinical Cancer Informatics. Thank you to the Alberta Cancer Foundation and many others for their support.

AUTHOR: AUTHOR: MARIA CUTUMISU, CATALINA VASQUEZ, MAXWELL UHLICH, PERRIN H. BEATTY, HOMEIRA HAMAYELI-MEHRABANI, RUME DJEBAH, ALBERT MURTHA, RUSSELL GREINER, AND JOHN D. LEWIS

Intravital imaging tumor screen used to identify novel metastasis-blocking therapeutic targets

October 4th, 2018|Publication|

This is a micro-review of an original research article from the Lewis research group that identified multiple novel metastasis-blocking targets, by using a whole genome screen and intravital imaging approach, that could be used as therapeutic targets to inhibit solid tumour cell motility.

AUTHOR: KONSTANTIN STOLETOV, LIAN WILLETTS, PERRIN H. BEATTY, AND JOHN D. LEWIS

Title

Go to Top